Cell One Partners has announced a strategic collaboration with the Center for Breakthrough Medicines (CBM) to expedite the development and commercialisation of cell and gene therapies.

Cell One Partners offers virtual company creation and management to its clients for complete aspects of the development and commercialisation of drugs.

The collaboration combines the virtual executive leadership and programme management of Cell One Partners with the technologies, capabilities, and capacity of CBM for the development, testing, and manufacturing of therapies.

The virtual company creation of Cell One Partners helps in removing the barriers to access to senior C-suite leadership by providing virtual management at one-third of the cost of a traditional new start-up company.

This allows the asset owners to focus their cash and energies on research and development.

With the collaboration with CBM, the cell and gene therapy asset owners will get access to end-to-end services for supporting process development, research and development, and clinical and commercial manufacturing, including starting materials along with cell banking.

Cell One Partners founder and CEO George Goldberger said: “Our unique model of creating and managing virtual companies for CGT asset owners allows them to accelerate their pathway to commercialization via our unparalleled network of cell and gene therapy leaders and innovators to support all aspects of the development, manufacturing, and commercialisation continuum at about one-third of the management cost of setting up a traditional company with C-level executives.

“The Center for Breakthrough Medicines is a valuable asset to our clients as their integrated, end-to-end services, all located in a single complex, allow innovator companies to optimise their working capital and focus on driving the science toward commercialisation.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.